68 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Immunotherapy
  • Germany
  • World
  • Product Initiative
  • Anergis SA

The goal was to demonstrate safety and efficacy of recombinant Bet v ## for desensitization against birch pollen allergy.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Therapy
  • Anergis SA
  • AM-101 - DRUG PROFILE

House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H## 2019 ZHEJIANG I-BIOLOGICAL TECHNOLOGY CO LTD House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUS

  • Immunotherapy
  • Medical Biotechnology
  • World
  • Product Initiative
  • Anergis SA
  • Cedar Pollen Allergy - Drug Profiles
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Immunotherapy
  • Medical Biotechnology
  • Japan
  • World
  • Product Initiative
  • Vaccine for Grass Pollen Allergy - Drug Profile
  • Vaccine for Grass Pollen Allergy - Drug Profile

Vaccine ## for Grass Pollen Allergy - Drug Profile Vaccine for Grass Pollen Allergy - Drug Profile Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Vaccine for Grass Pollen Allergy DC##U B

  • Allergy
  • Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • BM-34 - Drug Profile

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Immunotherapy
  • Therapy
  • United States
  • World
  • Product Initiative
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE
  • BM-34 - Drug Profile

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • ALLERGEN FOR PEANUT ALLERGY - DRUG PROFILE
  • R&D Progress

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Chronic Disease
  • Immunotherapy
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy Drug
  • Immunotherapy
  • Canada
  • United States
  • Product Initiative
  • Cedar Pollen Allergy - Drug Profiles
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Immunotherapy
  • Japan
  • World
  • Product Initiative
  • Vaccine 1 for Grass Pollen Allergy - Drug Profile
  • Vaccine for Grass Pollen Allergy - Drug Profile

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Biotechnology
  • Immunotherapy
  • Therapy
  • Regeneron Pharmaceuticals, Inc.
  • ALLERGEN FOR PEANUT ALLERGY - DRUG PROFILE
  • R&D Progress

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • United States
  • Aimmune Therapeutics, Inc.

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Immunotherapy
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative
  • QBKPN-SSI - DRUG PROFILE

The drug candidate targets the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Immunotherapy
  • United States
  • Company
  • AstraZeneca PLC

The drug candidate is a human immunoglobulin monoclonal antibody targeting eotaxin-##.

  • Chronic Disease
  • Immunotherapy
  • United States
  • Company
  • Product Initiative

Drug Allergy- The allergy from medicines, drugs is the most common form of allergy.

  • Immunotherapy
  • Respiratory Disease
  • World
  • Merck & Co., Inc.
  • Stallergenes Greer plc
  • UB-221 - DRUG PROFILE
  • QBKPN-SSI - DRUG PROFILE

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Immunotherapy
  • Pharmaceutical
  • Research And Development
  • AstraZeneca PLC

The hypersensitivity of the body to sun rays causes sun allergy. ##. ## Types of Allergy by Allergens Drug Allergy-The allergy from medicines, drugs is the most common form of allergy.

  • Allergy Immunotherapy
  • Immunotherapy
  • World
  • Market Size
  • Allergy Therapeutics plc

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Immunotherapy
  • Therapy
  • Bristol-Myers Squibb Company

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy Drug
  • Immunotherapy
  • Medical Biotechnology
  • Ophthalmic Solution
  • Allergy Therapeutics plc
  • MEPOLIZUMAB - DRUG PROFILE

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Digestive System Disorder
  • Immunotherapy
  • Therapy
  • United States
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## AnaptysBio Inc ## ## ## ## ## Food Allergy Research & Education Inc ## ## ## ## ## Novartis AG ## ## ## ## ## Droege International Group AG ## ## ## ## ## Allertein Therapeutics LLC ## ## ## ## ## Allergy Therapeutics

  • Allergy
  • Clinical Trial
  • Immunotherapy
  • Medical Biotechnology
  • Aimmune Therapeutics, Inc.
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate is in Phase II stage for peanut allergy, grass pollen allergy, chronic urticaria, and dermatitis globally.

  • Immunotherapy
  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Immunotherapy
  • Therapy
  • Bristol-Myers Squibb Company
  • 7.4 STRATEGIES TO MINIMIZE SIDE EFFECTS IN IMMUNOTHERAPY PROTOCOLS

WORLD ALLERGY ORGANIZATION JOURNAL, ##(##), PP. ##-##.

  • Immunotherapy
  • Australia
  • World
  • Forecast
  • Aimmune Therapeutics, Inc.

The LUTE / VERSE findings were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Diego, California, US.

  • Asthma
  • Immunotherapy
  • Medical Biotechnology
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Immunotherapy
  • Therapy
  • Canada
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • Jun 06, 2017: Allergy Therapeutics: Directorate changes

He has previously spent over six years working at the US Food and Drug Administration (FDA) as a Medical Officer and Medical Team Leader in the Division of Pulmonary-Allergy Drug Products.

  • Immunotherapy
  • Europe
  • United States
  • Company Financials
  • Allergy Therapeutics plc
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Immunotherapy
  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.